Mounjaro™ (tirzepatide) injection
Approval Date: May 2022
Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise
Farxiga (dapgliflozin) tablets
Approval Date: Feb 2022
A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.
Rezvoglar (insulin glargine-aglr) injection
Approval Date: Dec 2021
Indicated to improve glycemic control for type 1 and 2 diabetes
Jentadueto® (linagliptin and metformin hydrochloride) tablets
Approval Date: Aug 2021
Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes
Tradjenta® (linagliptin) tablets
Approval Date: Aug 2021
Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes
Januvia® (sitagliptin) tablets
Approval Date: Sep 2021
A once-daily medication indicated to help lower blood sugar with type 2 diabetes, in conjunction with diet and exercise
Semglee® (insulin glargine-yfgn) injection for subcutaneous use
Approval Date: Jul 2021
This is the first time a generic has been approved for Semglee. For the treatment of Type 1 and Type 2 diabetes, this drug is both a biosimilar to, and interchangeable with Lantus (insulin glargine)
ZEGALOGUE® (DASIGLUCAGON) INJECTION FOR SUBCUTANEOUS USE
Approval Date: Mar 2021
For the treatment of severe hypoglycemia in diabetic patients